Genprex, Inc. Material Events - What Happened

Hey everyone, let's break down some important news from Genprex, Inc. in a way that makes sense, even if you're not a Wall Street wizard. Think of this as me explaining it to you over coffee.

---

Part 1: Positive Early Results for Lung Cancer Drug (REQORSA)

1. What happened? (The actual event, in plain English)

Genprex, a company focused on developing new gene therapies, just announced some really positive early results from their ongoing drug testing. Specifically, their main drug candidate, called REQORSA, which is being developed to treat a tough type of lung cancer (non-small cell lung cancer, or NSCLC), showed some promising signs in patients.

In simple terms: Their experimental lung cancer drug is looking good in early human trials.

2. When did it happen?

The company officially shared these results in a press release and a filing with the SEC (that's the government body that oversees public companies) on Tuesday, October 24th, 2023.

3. Why did it happen? (Context and background)

Okay, so Genprex is a "biotech" company. That means they're in the business of creating new medicines, often using advanced science like gene therapy. Developing a new drug is a long, expensive, and risky process. It involves several stages of "clinical trials" (human testing) to prove the drug is safe and actually works.

• REQORSA is their flagship drug. It's designed to target cancer cells in a unique way, essentially trying to make them more responsive to other cancer treatments.
• The news came from an interim analysis of their Phase 1/2 clinical trial. Think of "interim analysis" as checking the scoreboard halfway through the game. They're looking at how patients are doing before the trial is completely finished.
• These positive results mean that the drug is not only showing it's safe enough for patients, but it's also starting to show signs that it's actually helping them – either by shrinking tumors or stopping the cancer from growing. This is a big deal for a drug in development.

4. Why does this matter? (Impact and significance)

This is a material event because it's a piece of information that could significantly change how people view the company and its future.

• For the company: Positive trial results are like hitting a major milestone. It increases the chances that REQORSA will eventually make it to market, which is how biotech companies make money. It also makes it easier for them to raise more money for future development.
• For patients: If REQORSA continues to perform well, it could eventually become a new treatment option for people suffering from a very serious and often deadly form of lung cancer. This offers hope.
• For the stock: News like this often causes a company's stock price to jump (or fall, if the news were bad). It signals to investors that the company's main product is on the right track.

5. Who is affected?

• Patients with NSCLC: This news offers potential hope for a new treatment.
• Genprex employees: Good news boosts morale and job security.
• Genprex investors (shareholders): Their investment could become more valuable.
• Doctors and researchers: They'll be watching these results closely as they could influence future treatment strategies.
• Competitors: Other companies developing lung cancer treatments will be paying attention to Genprex's progress.

6. What happens next? (Immediate and future implications)

This isn't the finish line, but it's a strong step forward.

• More testing: Genprex will continue with this Phase 1/2 trial and, if all goes well, move into a larger Phase 3 trial. This is the final, biggest test before they can ask for approval.
• Regulatory approval: If Phase 3 is successful, they'll submit all their data to the FDA (Food and Drug Administration) in the U.S. (and similar bodies elsewhere) to get permission to sell the drug. This process can take a year or more.
• Funding: These positive results make it easier for Genprex to attract more investment or even partner with a larger pharmaceutical company to help fund the expensive later stages of development.

---

Part 2: Nasdaq Listing Compliance Update

1. What happened? (The actual event, in plain English)

Genprex received good news from Nasdaq (the stock exchange where their shares are traded). Nasdaq confirmed that Genprex has regained compliance with one of its important financial rules. This means the company is no longer at immediate risk of being delisted from the exchange for that specific reason.

2. When did it happen?

Genprex was formally notified of this compliance on January 7, 2026. The company then filed this information with the SEC on January 9, 2026.

3. Why did it happen? (Context and background)

Public companies like Genprex need to meet certain standards to have their stock traded on exchanges like Nasdaq. One of these rules, called the Minimum Stockholders’ Equity Rule, requires companies to have at least $2.5 million in shareholder equity (which is basically the company's assets minus its liabilities – a measure of its financial health).

• Genprex had previously fallen below this $2.5 million threshold, which put their listing on Nasdaq at risk.
• They've now shown Nasdaq that they meet this financial requirement again, likely by improving their financial position.

4. Why does this matter? (Impact and significance)

This is a big deal for a public company:

• For the company: It means their stock can continue to be traded on Nasdaq, which is a major, reputable exchange. Being delisted can make it much harder for investors to buy and sell shares, and it can damage a company's reputation and ability to raise money.
• For investors: It removes an immediate financial risk factor. Your shares can continue to be easily traded on Nasdaq. However, there's a catch...

5. Who is affected?

• Genprex investors (shareholders): Their ability to trade shares on Nasdaq is secured for now.
• Genprex management: They've successfully addressed a critical financial compliance issue.
• Nasdaq: Maintains the integrity of its listing standards.

6. What happens next? (Immediate and future implications)

While Genprex is compliant now, they are on a "mandatory panel monitor" (think of it as a probation period) for one year, until January 7, 2027.

• During this year, if Genprex falls below the $2.5 million minimum stockholders' equity rule again, they won't get another chance to submit a plan to fix it.
• Instead, Nasdaq would immediately issue a delisting notice, and the company would face a much faster path to potentially being removed from the exchange. They would still get a hearing, but the process would be accelerated and less forgiving.
• So, while the immediate threat is gone, the company needs to be extra careful with its financial health over the next year.

---

Overall Takeaways for Investors/Traders

7. What should investors/traders know? (Practical takeaways)

• Volatility: Biotech stocks, especially those with drugs in development, can be very volatile. Good news (like drug trial results) can send the stock soaring, but future bad news (like a failed trial or financial non-compliance) can send it crashing.
• Long-term vs. Short-term: For day traders, the drug news might be a quick opportunity. For long-term investors, the drug trial results are a positive sign for the company's future product, but the Nasdaq compliance news highlights ongoing financial management needs.
• Risk: Even with positive early drug results, there's still significant risk in drug development. Additionally, while the immediate delisting threat is gone, the one-year monitoring period means Genprex's financial health remains a critical factor to watch. Falling out of compliance again during this period would be a serious setback.
• Do your homework: Don't just jump in because of a headline. Look at the company's overall financial health, how much cash they have, and what other drugs they have in their pipeline. Understand that drug development is a long journey, and financial stability is crucial for that journey.

In short, Genprex just got a significant thumbs-up for their main drug, and they've also successfully navigated a critical financial hurdle with Nasdaq. Both are positive developments, but for investors, it's a reminder that while the potential for their drug is exciting, the journey to a marketable drug is still far from over, and the company's financial stability remains under scrutiny.